In brief: Prima, SciGen, Sonic
Thursday, 30 June, 2005
The executive director of the Austin Research Institute, Mark Hogarth, has resigned as a director of Prima Biomed (ASX:PRR). The company cited Hogarth's increased responsibilities at the ARI for his resignation.
SciGen (ASX:SIE) managing director and CEO Mark Compton will leave the company on August 5. While he will remain as CEO till then, he has resigned as a director, effective June 29. SciGen is searching for a new CEO who is likely to be based in Asia.
Former CEO and executive director of the Melbourne Pathology Group, Lou Panaccio has joined the board of Sonic Healthcare (ASX:SHL) as a non-executive director. He will also replace Colin Jackson as a member of the Audit Committee.
Targeting 'molecular bodyguards' weakens prostate cancer cells
Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...
Females found to carry a higher genetic risk of depression
An international team of scientists has discovered about twice as many genetic 'flags'...
Widespread resistance to common antibiotics is increasing: WHO
Increasing resistance to essential antibiotics poses a growing threat to global health, with one...
